Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0278488 (
metastatic breast cancer
)
7,812
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
LASP-1
is an actin-binding protein that regulates cytoskeletal dynamics and cell migration.
LASP-1
was previously identified in a cDNA library from
metastatic breast cancer
samples. This protein has since been detected in multiple human cancers, including liver cancer, gastric cancer and pancreatic cancer. S100P is a small calcium-binding protein in the S100 protein family that regulates cellular, physiological and pathological processes in various cancers. However, the clinical significance of
LASP-1
and S100P expression in gallbladder cancer (GBC) is not yet clear. In our study, we focused on the clinical significance, biological function and mechanism of
LASP-1
in gallbladder cancer and detected
LASP-1
and S100P overexpression in GBC tissues. The expression of
LASP-1
was significantly correlated with poor prognosis in GBC patients (P < 0.05). Furthermore, down-regulation of
LASP-1
expression resulted in the obvious inhibition of proliferation and migration and caused cell cycle arrest by down-regulating S100P via the PI3K/AKT pathway; in mice, tumor volume was significantly decreased. In conclusion,
LASP-1
may act as an oncogene to regulate the expression of S100P to influence cellular functions in GBC.
LASP-1
could serve as a genetic treatment target in GBC patients.
...
PMID:LASP-1 induces proliferation, metastasis and cell cycle arrest at the G2/M phase in gallbladder cancer by down-regulating S100P via the PI3K/AKT pathway. 2712 25
